Neola Medical AB (publ) (NEOLA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

We welcome viewers to this live broadcast where Neola Medical has published their fourth and final report for the fiscal year of 2025. And joining us here in the digital studio is CEO Hanna Sjöström as well as CFO David Folkesson. And we'll turn to Hanna, of course. Welcome, Hanna. Thank you so much. You will give us a presentation. Afterwards, I'll return to ask some questions. And I would also like to remind viewers here who are watching to post your questions in the live chat during the broadcast, and I will ask them in the Q&A. So Hanna, go ahead. Well, a very warm welcome to everyone joining today. So today we will present Neola Medical's year-end Q4 report for 2025 and our Summarizing a year marked by key milestones as we this year really entered the clinical phase, strengthened the organization and continued to build on our strategically important assets. And presenting here today is myself, Hanna Sjöström, I'm CEO of Nyhåla Medical since 2019 and CFO David Folkesson. First, I will present the company, the market and significant events during the full year of 2025 and also, of course, during the quarter. And thereafter, David Falkesson will walk you through the numbers and the financial summary. Before we begin, please do note that today's presentation may include forward-looking statements. Actual results may differ due to risks and uncertainties. including market conditions, regulatory processes, and execution of our strategies. Neola Medical is a deep tech company developing a class two medical device, Neola, neonatal lung analyzer. And it's designed for noninvasive and continuous lung monitoring of preterm born babies. The company was founded in 2016, and we have our headquarters in Lund, where I'm presenting today. The technology behind Neola is based on ...